What this pack is
Ganaton / Elthon is the brand name in this record; itopride hydrochloride is the generic name. Read both together with the dosage form (exact dosage form to be checked from the current pack).
PACK CHECK · MARKET FIRST
Ganaton / ElthonGeneric nameitopride hydrochloride
Mainland China pack-name cue为力苏®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
Itopride supports the acetylcholine signals that drive gut movement by blocking dopamine D2 receptors and reducing acetylcholine breakdown.
Read source: Mainland China ↗reviewed 2026-09-09More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 为力苏®
- International brand name
- Ganaton / Elthon
- Source-scoped market brand names
- 为力苏® / Elthon® · Mainland ChinaSource-scoped evidence ↗Abbott China’s page and leaflet identify the brand and 50 mg strength.
- ガナトン / Ganaton · JapanSource-scoped evidence ↗The PMDA label lists Ganaton 50 mg and authorisation 20700AMZ00550.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- itopride hydrochloride
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
Mainland China trade-name search cue:为力苏®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
2 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
JP · Public PMDA label, July 2024, fourth revision
50 mg itopride hydrochloride per tablet; 100-tablet pack
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- 20700AMZ00550
- Form and route
- Itopride hydrochloride film-coated tablets · Oral (product-identity field)
- Listing review
- Cited product evidence reviewed 2026-09-09; actual marketing, stock and availability are not established.
- itopride hydrochloride
- 50 mgStrength per tablet, not an individual dose
- Package
- 100 tablets per pack
JP · Public PMDA label, July 2024, fourth revision
50 mg itopride hydrochloride per tablet; 1000-tablet pack
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- 20700AMZ00550
- Form and route
- Itopride hydrochloride film-coated tablets · Oral (product-identity field)
- Listing review
- Cited product evidence reviewed 2026-09-09; actual marketing, stock and availability are not established.
- itopride hydrochloride
- 50 mgStrength per tablet, not an individual dose
- Package
- 1000 tablets per pack
PACKAGE-VISUAL STATUS
Tablet features can be checked; exact carton photo not shown
China describes a white film-coated tablet; Japan specifies a white scored tablet marked HC803. Japanese 100/1000-tablet packs are not Chinese packs. No retail or other-market photograph is substituted, and appearance alone cannot authenticate a medicine.
LABEL READING · NOT A PRESCRIPTION
Large-print leaflet reading: strength, older adults and splitting
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
Start with the Chinese Elthon original, revised 25 September 2025. Its front covers uses, splitting and contraindications; the reverse covers older adults, interactions and approval identifiers. Read both sides.
- Each tablet contains 50 mg; the Chinese leaflet lists 10- and 20-tablet cartons. Pack count is not the dose. Confirm your individual amount and schedule against the prescription.
- This Chinese product’s leaflet permits tablet division when adjusting for age and symptoms. Confirm whether your prescriber intends splitting; this does not apply to every stomach medicine or modified-release product.
- Older adults may be more susceptible to adverse effects. If dizziness, agitation or impaired reactions occur, avoid hazardous activities such as driving and contact your clinician or pharmacist.
- The Chinese product is contraindicated with gastrointestinal bleeding, mechanical obstruction, perforation or allergy to its ingredients. Persistent pain or vomiting should not simply be treated as poor gut motility.
- Breathing difficulty, throat swelling or fainting with a severe allergic reaction requires emergency help; jaundice or other concerning changes require prompt assessment.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkAbbott China · Mainland China · Manufacturer public leaflet · 2026-09-09
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- Mainland China · 2
- Japan · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeAbbott China: Elthon itopride hydrochloride leaflet, front; revised 25 September 2025 ↗reviewed 2026-09-09
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- Abbott China · Mainland China · Manufacturer public leaflet · 2026-09-09Abbott China: Elthon leaflet, reverse; older adults, interactions and approval identifiers ↗reviewed 2026-09-09
- PMDA · Japan · Regulatory product record · 2026-09-09PMDA: Ganaton Tablets 50mg, 20700AMZ00550; electronic label revised July 2024 ↗reviewed 2026-09-09
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Ganaton / Elthon (itopride hydrochloride). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Ganaton / Elthon is the brand in this record and itopride hydrochloride is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- Abbott China: Elthon itopride hydrochloride leaflet, front; revised 25 September 2025 ↗reviewed 2026-09-09
- Abbott China: Elthon leaflet, reverse; older adults, interactions and approval identifiers ↗reviewed 2026-09-09
- PMDA: Ganaton Tablets 50mg, 20700AMZ00550; electronic label revised July 2024 ↗reviewed 2026-09-09
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
Also using Motilium / domperidone?
These contain different ingredients. Similar uses do not establish suitability for combination or alternation; have the actual packs, schedule and symptoms reviewed professionally.
Open the Motilium / domperidone record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-09-09HOW IT WORKS · NOT A TREATMENT PLAN
Helps gut movement; it is not an acid suppressant
- It is not domperidone or mosapride. A shared prokinetic purpose does not justify combining, alternating or converting doses yourself.
- Anticholinergics may reduce its effect. Changed gut movement can also affect absorption of other oral medicines, especially narrow-therapeutic-index, prolonged-release or enteric-coated products.
- Predominant FMO-related metabolism does not mean no interactions. The Chinese leaflet also warns about QT prolongation and abnormal liver function.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- Abbott China: Elthon itopride hydrochloride leaflet, front; revised 25 September 2025 ↗reviewed 2026-09-09
- Abbott China: Elthon leaflet, reverse; older adults, interactions and approval identifiers ↗reviewed 2026-09-09
- PMDA: Ganaton Tablets 50mg, 20700AMZ00550; electronic label revised July 2024 ↗reviewed 2026-09-09
- Abbott China: digestive products and current Elthon leaflet downloads ↗reviewed 2026-09-09
SOURCE-TRACEABLE ARCHIVE
Ganaton / Elthonitopride hydrochloride
This page links to public primary-source material for Ganaton / Elthon. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Ganaton sales began in Japan
A market-specific sales date printed in the Japanese label, not a global-first claim.
PMDA: Ganaton Tablets 50mg, 20700AMZ00550; electronic label revised July 2024 ↗Chinese Elthon leaflet revised
The front and reverse reached from Abbott’s current product page carry artwork code 10-014R7.
Abbott China: Elthon itopride hydrochloride leaflet, front; revised 25 September 2025 ↗
MARKET SCOPE
Market-record boundary
Mainland China
First-party public leaflet checkedThe leaflet lists HJ20160414/HJ20160415 and 10/20-tablet cartons without mapping each identifier to a pack. No pairing is invented, and a separate current NMPA database check is not completed.
Japan
Public PMDA electronic label checkedThe original is revised July 2024 and lists 50 mg in 100/1000-tablet packs. Access verification is not a new label revision or live inventory check.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Is 50 mg the total tablet weight?
No. It is the labelled itopride hydrochloride content per tablet. The Japanese label separately gives a 130 mg tablet weight including excipients; that does not mean a 130 mg itopride dose.
Does a score mean I should halve my dose?
Whether a tablet can be divided and what dose you need are separate questions. The Chinese Elthon leaflet permits division for dose adjustment, but the clinical decision is individual. Check other brands separately.
Can I keep taking it indefinitely as a stomach medicine?
No. The Chinese leaflet notes the lack of long-term use data and advises discontinuation if improvement is unclear after two weeks. Contact the prescribing team for reassessment rather than increasing or adding another prokinetic yourself.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.